Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Ranibizumab for Rubeosis Iridis
NCT02641457Phase 3Completed
- Sponsor
- Instituto de Olhos de Goiânia
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of aflibercept and ranibizumab in rubeosis iridis (NVI) and neovascular glaucoma (NVG), sponsored by Instituto de Olhos de Goiânia. Primary endpoint: Degree of rubeosis iridis by biomicroscope at 1 year. Started Mar 2014; status: completed.
02
Drugs
afliberceptranibizumab
03
Conditions
rubeosis iridis (NVI)neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT02641457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641457.